SOFIE
SOFIE is a privately held radiopharmaceutical company operating 15 U.S. manufacturing and radiopharmacy sites that produce over 567,000 PET doses annually and supply its lead FAPI-based diagnostic tracer [18F]FAPI-74 — currently in two Phase 3 oncology trials — to hospitals, imaging centers, pharmaceutical companies, and academic institutions.
- Company typePrivate
- Founded2008
- HeadquartersCulver City, United States
- Headcount251–500
- GTM typeB2B
- OfferingServices
What SOFIE does
SOFIE is a privately held radiopharmaceutical company operating a vertically integrated platform for PET diagnostics and theranostics manufacturing, headquartered in Dulles, Virginia and founded in 2008. The company runs 15 U.S. manufacturing and radiopharmacy locations — including sites in Totowa NJ, Gilroy CA, Romeoville IL, Cleveland OH, Sanford FL, Kansas City MO, Houston TX, and Decatur IL — producing over 567,000 doses annually through 14+ network sites committed to on-time delivery. Its proprietary core asset is [18F]FAPI-74, a fluorine-18 radiolabeled PET tracer targeting Fibroblast Activation Protein (FAP), licensed from Heidelberg University Hospital and now advancing through two Phase 3 clinical programs: FAPI-GO for gastroesophageal cancers and FAPI-PRO for pancreatic ductal adenocarcinoma.
The company generates revenue across three streams: (1) direct manufacturing and distribution of PET radiopharmaceuticals (including common tracers and proprietary FAPI products) to hospitals, imaging centers, and healthcare systems via its radiopharmacy network; (2) contract manufacturing / CDMO services to pharmaceutical and academic clients, channeled through its Theranostics Center of Excellence for clinical trial material and commercial supply; and (3) supply and licensing arrangements for FAPI-based diagnostic and companion-diagnostic agents, including an agreement to supply [18F]FAPI-74 to Eli Lilly's FiREBOLT FAP Radioligand Therapy study. Pricing is quote-based and not publicly disclosed. Go-to-market is enterprise-direct and sales-led, targeting pharmaceutical companies, healthcare systems, and academic medical centers.
Distribution is handled through the company's owned radiopharmacy network, with extended product shelf-life (12 hours post-End of Synthesis) and an 8-hour delivery radius from activated sites enabling broad domestic coverage. Marketing and education outreach is conducted through scientific conferences (SNMMI, EANM, ASCO GI), peer-reviewed publications, webinars, a quarterly "Focus on FAPI" newsletter, and an educational hub aimed at PET imaging practitioners. The leadership team is led by Patrick Phelps (President and CEO), with Sherly Mosessian, PhD as Chief Scientific Officer; ownership includes a 2024 growth investment from Trilantic North America.
SOFIE firmographics
Firmographics- Name
- SOFIE
- Legal name
- SOFIE Co.
- Website
- https://sofie.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- SOFIE is a privately held radiopharmaceutical company operating 15 U.S. manufacturing and radiopharmacy sites that produce over 567,000 PET doses annually and supply its lead FAPI-based diagnostic tracer [18F]FAPI-74 — currently in two Phase 3 oncology trials — to hospitals, imaging centers, pharmaceutical companies, and academic institutions.
- Ownership category
- akta.pro rank
SOFIE industry classification
Industry- Product category
- Radiopharmaceutical Manufacturing and Distribution
- NAICS
- Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Health Services (8000), Surgical & Medical Instruments & Apparatus (3841), Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)
- akta.pro secondary industries
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)
Keywords
Where SOFIE is headquartered
LocationHeadquarters
- HQ city
- Culver City
- HQ country
- United States
- HQ region
- North America
Offices9 records
Markets served
SOFIE business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain
Revenue model
- Radiopharmaceutical Manufacturing and Distribution: Manufacturing and distribution of PET radiopharmaceuticals through company-owned radiopharmacy network. Produces over 567,000 doses annually across 15 U.S. locations for diagnostic imaging services.
- Contract Manufacturing (CDMO Services): Provides contract manufacturing services to pharmaceutical companies and academic institutions through its network and Theranostics Center of Excellence for clinical needs.
- FAPI Clinical Trial Support: Supply of [18F]FAPI-74 for pharmaceutical collaborations including Lilly's FiREBOLT FAP Radioligand Therapy study and academic investigator-initiated studies.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
SOFIE product offering
Product offeringCore offering
SOFIE is a radiopharmaceutical company that manufactures and distributes PET (positron emission tomography) radiopharmaceuticals through its network of radiopharmacies across the United States. It operates a vertically integrated business spanning proprietary diagnostic tracer development (lead asset [18F]FAPI-74 targeting Fibroblast Activation Protein for GI cancers), GMP-compliant contract development and manufacturing (CDMO) services for clinical and commercial supply, and a Theranostics Center of Excellence serving pharmaceutical, academic, and healthcare provider customers.
Product overview
SOFIE is a radiopharmaceutical company offering a portfolio of diagnostic PET tracers and contract manufacturing services. The core product is [18F]FAPI-74, a fluorine-18 labeled radiopharmaceutical targeting Fibroblast Activation Protein (FAP) for cancer imaging. The company operates a network of 14+ radiopharmacies producing over 567,000 doses annually, provides CDMO contract manufacturing services, and has a Theranostics Center of Excellence. SOFIE also runs clinical development programs including Phase 3 trials (FAPI-GO for gastroesophageal cancers and FAPI-PRO for pancreatic cancer), an educational hub for PET imaging, and a FAPI Outreach Program for research collaboration.
Differentiator
Problem solved
Functional benefit
Products and services
- [18F]FAPI-74 PET Tracer
Quantifiable outcome
- 100% positive predictive value in detecting FAP-expressing cells
- +3 more outcomes
Companies that use SOFIE
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
SOFIE technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
SOFIE partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- RadNetcoreClinical trial partnership for Phase 3 FAPI-GO study. RadNet provides imaging capabilities through its national network of 407 outpatient imaging centers. RadNet's Director of PET/CT and Research, Judith Rose MD, serves as principal investigator.
- Helios Clinical ResearchcoreClinical trial network dedicated to accelerating access to innovative therapies through high-quality, patient-centered research. In partnership with The Oncology Institute of Hope and Innovation, Helios embeds clinical trials into real-world care settings.
- The Oncology Institute of Hope and InnovationminorNationally recognized leader in community-based oncology care collaborating with Helios Clinical to expand access to cutting-edge cancer clinical trials.
- Heidelberg University Hospital (UKHD)coreLicensor of FAPI (quinoline-based PET tracers acting as FAP inhibitors) technology developed by the team at Heidelberg University Hospital. SOFIE holds license for FAPI development and commercialization.
- Eli Lilly and CompanycoreSOFIE is a supplier of [18F]FAPI-74 for Lilly's FiREBOLT FAP Radioligand Therapy study (NCT07213791), supporting pharmaceutical collaboration in radiotheranostics.
Scale indicators8 records
Recent moves9 records
Expansion highlights7 records
SOFIE competitors and assessment
Company assessmentBroad incumbents
- Bracco Imaging: Bracco is a global imaging agent company with a portfolio spanning contrast media and radiopharmaceuticals, providing a broader-market analog to SOFIE's diagnostic imaging focus with global distribution reach SOFIE lacks.
- GE HealthCare (Radiopharma): GE HealthCare operates a global radiopharmacy and PET tracer manufacturing footprint as part of its broader imaging and diagnostics portfolio, overlapping with SOFIE on commercial distribution but with materially greater scale and capital resources.
- Novartis (Pluvicto / radioligand therapy franchise): Novartis pioneered commercial radioligand therapy with Pluvicto/Lutathera, establishing the theranostic Dx/Tx paradigm that SOFIE is building toward with FAPI-74 and its Lilly-supplied FAP therapy program.
Direct peers
- Telix Pharmaceuticals: Telix develops and commercializes radiopharmaceuticals for cancer imaging and therapy, including PSMA-targeted agents; its companion-diagnostic-plus-therapy model parallels SOFIE's FAPI-74 / Lilly FiREBOLT theranostic positioning.
- Curium Pharma: Curium is a global radiopharmaceutical company manufacturing and distributing PET and SPECT tracers, with vertical integration across manufacturing, distribution, and contract services — a near-identical operating model to SOFIE.
- PETNET Solutions (Siemens Healthineers): PETNET Solutions operates a national U.S. radiopharmacy network producing and distributing PET radiopharmaceuticals for hospitals and imaging centers, making it the most direct operational peer to SOFIE's 15-site distribution business.
- Cardinal Health Nuclear & Precision Health Solutions: Cardinal Health operates a large U.S. nuclear pharmacy and radiopharmaceutical distribution network serving hospitals and imaging centers, directly competing with SOFIE's commercial dose distribution franchise.
- Lantheus Holdings: Lantheus is a radiopharmaceutical-focused company with proprietary diagnostic agents (e.g., PYLARIFY) and CDMO services, comparable to SOFIE's combined FAPI-74 pipeline plus commercial distribution and contract manufacturing business.
Emerging players
- Blue Earth Diagnostics: Blue Earth Diagnostics develops and commercializes PET radiopharmaceuticals for cancer imaging, sharing SOFIE's diagnostic oncology focus with a more limited pipeline and narrower indication footprint.
Regional players
- Jubilant Pharmova (Jubilant Biosys / Radiopharma): Jubilant is an existing SOFIE investor (lead in the 2020 round) and operates radiopharmaceutical and contract manufacturing businesses primarily outside the U.S., making it a comparable CDMO/radiopharma peer with a different geographic footprint.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
SOFIE social profiles
Digital presenceSOFIE financial estimates
Financial estimateRevenue estimate
Valuation estimate
SOFIE leadership team
Management profileNumber of profiles
Profiles1 record
SOFIE funding detail
Funding detailFunding overview
Funding rounds7 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SOFIE M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SOFIE
What does SOFIE do?
SOFIE is a radiopharmaceutical company that manufactures and distributes PET (positron emission tomography) radiopharmaceuticals through its network of radiopharmacies across the United States. It operates a vertically integrated business spanning proprietary diagnostic tracer development (lead asset [18F]FAPI-74 targeting Fibroblast Activation Protein for GI cancers), GMP-compliant contract development and manufacturing (CDMO) services for clinical and commercial supply, and a Theranostics Center of Excellence serving pharmaceutical, academic, and healthcare provider customers.
Is SOFIE a public or private company?
SOFIE is a private company. It is classified as venture growth investor backed and is currently operating.
When was SOFIE founded?
SOFIE was founded in 2008. It employs 251 to 500 people.
Where is SOFIE based?
SOFIE is headquartered in Culver City, United States, in the North America region.
How does SOFIE make money?
Three revenue lines are on record. Radiopharmaceutical Manufacturing and Distribution is the primary driver. The others are contract Manufacturing (CDMO Services) and FAPI Clinical Trial Support.
Who are SOFIE's main competitors?
Broad incumbents on record are Bracco Imaging, GE HealthCare (Radiopharma) and Novartis (Pluvicto / radioligand therapy franchise). Direct peers are Telix Pharmaceuticals, Curium Pharma, PETNET Solutions (Siemens Healthineers), Cardinal Health Nuclear & Precision Health Solutions and Lantheus Holdings. Blue Earth Diagnostics is listed as an emerging player. Jubilant Pharmova (Jubilant Biosys / Radiopharma) is listed as a regional player.
Does SOFIE have an API?
No public API is recorded for SOFIE.
What industry is SOFIE in?
SOFIE's product category is Radiopharmaceutical Manufacturing and Distribution. Its primary akta.pro industry code is HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx), with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 5417 and its SIC code is 8000.